Were Analysts Bullish Incyte Corporation (NASDAQ:INCY) This Week?

Incyte Corporation (NASDAQ:INCY) Logo
Investors sentiment decreased to 1.23 in Q2 2019. Its down 0.67, from 1.9 in 2019Q1. It is negative, as 39 investors sold Incyte Corporation shares while 128 reduced holdings. 65 funds opened positions while 140 raised stakes. 188.94 million shares or 0.12% more from 188.70 million shares in 2019Q1 were reported.
2,066 are owned by Winslow Evans Crocker. Baystate Wealth Mgmt Ltd Com invested in 0% or 20 shares. Amalgamated Commercial Bank holds 0.05% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 23,523 shares. Tarbox Family Office stated it has 10 shares. Gradient Ltd Liability Company holds 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY) for 13,617 shares. Sands Capital Management Ltd Liability holds 4.24 million shares. Barclays Public Ltd Company reported 370,124 shares stake. Quantitative Invest Mngmt Ltd Company holds 0.27% or 81,020 shares. Royal London Asset Management Limited owns 73,947 shares. Grandfield & Dodd Limited Liability Corp reported 8,895 shares. Sun Life Financial Inc, Ontario – Canada-based fund reported 145 shares. Aviva Public Limited Com invested 0.04% of its portfolio in Incyte Corporation (NASDAQ:INCY). Bnp Paribas Arbitrage Sa owns 309,667 shares. San Francisco Sentry Invest Group (Ca) owns 367 shares. Mengis Cap Mgmt has 2,600 shares.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

Among 8 analysts covering Incyte (NASDAQ:INCY), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Incyte has $11100 highest and $7500 lowest target. $91.13’s average target is 19.23% above currents $76.43 stock price. Incyte had 15 analyst reports since April 2, 2019 according to SRatingsIntel. Barclays Capital downgraded Incyte Corporation (NASDAQ:INCY) on Friday, May 3 to “Equal-Weight” rating. Oppenheimer upgraded it to “Outperform” rating and $10000 target in Thursday, September 5 report. As per Thursday, September 5, the company rating was reinitiated by Morgan Stanley. Morgan Stanley maintained Incyte Corporation (NASDAQ:INCY) on Wednesday, July 31 with “Equal-Weight” rating. Nomura maintained the stock with “Buy” rating in Wednesday, July 31 report. The stock has “Market Outperform” rating by JMP Securities on Thursday, September 5. Below is a list of Incyte Corporation (NASDAQ:INCY) latest ratings and price target changes.

12/09/2019 Broker: BMO Capital Markets Rating: Market Perform New Target: $85.0000 Initiates Coverage On
05/09/2019 Broker: JMP Securities Rating: Market Outperform New Target: $107.0000 Reinitiate
05/09/2019 Broker: Oppenheimer Old Rating: Perform New Rating: Outperform Old Target: $85.0000 New Target: $100.0000 Upgrade
05/09/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $82.0000 New Target: $87.0000 Reinitiate
31/07/2019 Broker: Nomura Rating: Buy Old Target: $100.0000 New Target: $111.0000 Maintain
31/07/2019 Broker: Morgan Stanley Rating: Equal-Weight Old Target: $81.0000 New Target: $82.0000 Maintain
22/05/2019 Broker: BidaskScore Rating: Hold Upgrade
21/05/2019 Broker: Credit Suisse Rating: Neutral New Target: $75.0000 Initiates Coverage On
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Old Target: $90.0000 New Target: $82.0000 Downgrade
03/05/2019 Broker: BidaskScore Rating: Sell Upgrade

The stock increased 0.47% or $0.36 during the last trading session, reaching $76.43. About 1.38 million shares traded or 15.90% up from the average. Incyte Corporation (NASDAQ:INCY) has risen 23.83% since September 13, 2018 and is uptrending. It has outperformed by 23.83% the S&P500.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. The company has market cap of $16.44 billion. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. It has a 53.79 P/E ratio. The companyÂ’s clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis.

More notable recent Incyte Corporation (NASDAQ:INCY) news were published by: Streetinsider.com which released: “Incyte (INCY) Announces Data from its Oncology Portfolio to be Featured at ESMO – StreetInsider.com” on September 03, 2019, also Nasdaq.com with their article: “INCY Makes Notable Cross Below Critical Moving Average – Nasdaq” published on September 04, 2019, Finance.Yahoo.com published: “Does Incyte (NASDAQ:INCY) Have A Healthy Balance Sheet? – Yahoo Finance” on August 13, 2019. More interesting news about Incyte Corporation (NASDAQ:INCY) were released by: Nasdaq.com and their article: “Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab – Nasdaq” published on July 03, 2019 as well as Nasdaq.com‘s news article titled: “Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? – Nasdaq” with publication date: August 29, 2019.

Incyte Corporation (NASDAQ:INCY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.